In the following video, Fool contributor Maxxwell Chatsko talks with health care analyst Max Macaluso and recaps the latest earnings results from the pharmaceutical industry. These companies each saw healthy gains in operating results and have big upcoming launches, such as Invokana from Johnson & Johnson (JNJ 6.19%) and Eliquis from Pfizer (PFE -0.10%). Nonetheless, investors will need to keep a long-term focus when viewing these complex pharmaceutical giants.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Big Pharma's Biggest Winners
NYSE: PFE
Pfizer

A Fool recaps first-quarter earnings bright spots around the pharmaceutical industry.
Fool contributor Maxx Chatsko and Max Macaluso, Ph.D. have no position in any stocks mentioned. Check out Maxwell's personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned




*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.